Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Cardiovascular Diabetology
Rafael SimóJacek Kiljański

Abstract

The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, it is important to determine whether glucose-lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in patients with type 2 diabetes treated with exenatide twice daily (a glucagon-like peptide-1 receptor agonist) or glimepiride (a sulfonylurea) added to metformin in the EURopean EXenAtide (EUREXA) study. Patients with type 2 diabetes failing metformin were randomized to add-on exenatide twice daily (n = 515) or glimepiride (n = 514) until treatment failure defined by hemoglobin A1C. Anthropomorphic measures, blood pressure (BP), heart rate, lipids, and high-sensitivity C-reactive protein (hsCRP) over time were evaluated. Over 36 months, twice-daily exenatide was associated with improved body weight (-3.9 kg), waist circumference (-3.6 cm), systolic/diastolic BP (-2.5/-2.6 mmHg), high-density lipoprotein (HDL)-cholesterol (0.05 mmol/L), triglycerides (-0.2 mmol/L), and hsCRP (-1.7 mg/L). Heart rate did not increase (-0.3 beats/minute), and low-density lipoprotein-cholesterol (0.2 mmol/L) and total cholesterol (0.1 mmol/L) increased slightly. Between-group differences were sign...Continue Reading

References

Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Apr 28, 2005·Diabetes Care·UNKNOWN Workgroup on Hypoglycemia, American Diabetes Association
Sep 18, 2007·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Prabhakar ViswanathanParesh Dandona
Sep 9, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Cindy J RubinFred T Fiedorek
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Aug 23, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Ajay VaranasiParesh Dandona
Feb 1, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·T ForstA Pfützner
Feb 11, 2012·British Journal of Clinical Pharmacology·Buddhike MendisPeter Mansell
Aug 16, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M L VetterUNKNOWN POWER-UP Research Group
Apr 4, 2014·European Journal of Internal Medicine·Asger LundTina Vilsbøll
Oct 24, 2014·Cardiovascular Diabetology·Francisco Kerr Saraiva, Andrei C Sposito
Apr 7, 2015·Diabetes Technology & Therapeutics·Eusebio ChiefariAntonio Brunetti

❮ Previous
Next ❯

Citations

Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Nov 25, 2016·Postgraduate Medicine·A Enrique Caballero
Jan 20, 2017·Expert Opinion on Drug Safety·Niels B DalsgaardFilip K Knop
Apr 1, 2017·Current Opinion in Cardiology·Niki KatsikiDimitri P Mikhailidis
Feb 1, 2018·Heart Failure Reviews·Vasiliki BistolaJohn Parissis
Jul 20, 2017·Diabetes, Obesity & Metabolism·Jin Won YangKeon Wook Kang
Apr 19, 2019·The Cochrane Database of Systematic Reviews·Kasper S MadsenBianca Hemmingsen
Mar 10, 2020·Clinical and Experimental Pharmacology & Physiology·Refaat A EidAttalla Farag El-Kott
Aug 9, 2017·Drug Development Research·Dominic N McBrayer, Yftah Tal-Gan
Jul 20, 2019·Therapeutic Advances in Chronic Disease·Olusola F OnoviranMukaila A Raji
Apr 3, 2020·Journal of Cardiovascular Translational Research·Refaat A EidMohammad A Khalil
Jan 20, 2016·Current Atherosclerosis Reports·Ashish SarrajuJoshua W Knowles
May 24, 2017·Diabetes·Rafael Simó, Cristina Hernández
Sep 27, 2016·International Journal of Environmental Research and Public Health·Omorogieva Ojo
Jan 15, 2017·Cardiovascular Diabetology·Martin LorenzLawrence Blonde
May 22, 2017·Current Cardiology Reports·Abeer AnabtawiJohn M Miles

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01144338

Software Mentioned

EUREXA

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.